418 related articles for article (PubMed ID: 18665971)
1. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
[TBL] [Abstract][Full Text] [Related]
2. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
Schmid DM; Roy S; Sulser T; Scheiner D
BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
5. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
Kuo HC
Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
[TBL] [Abstract][Full Text] [Related]
7. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years.
Stoehrer M; Wolff A; Kramer G; Steiner R; Lmöchner-Ernst D; Leuth D; Steude U; Ruebben H
Urol Int; 2009; 83(4):379-85. PubMed ID: 19996642
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
Pannek J; Göcking K; Bersch U
BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
[TBL] [Abstract][Full Text] [Related]
9. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.
Giannantoni A; Di Stasi SM; Stephen RL; Bini V; Costantini E; Porena M
J Urol; 2004 Jul; 172(1):240-3. PubMed ID: 15201783
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.
Do Ngoc Thanh C; Audry G; Forin V
J Pediatr Urol; 2009 Dec; 5(6):430-6. PubMed ID: 19577520
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
[TBL] [Abstract][Full Text] [Related]
12. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
13. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions.
Klaphajone J; Kitisomprayoonkul W; Sriplakit S
Arch Phys Med Rehabil; 2005 Nov; 86(11):2114-8. PubMed ID: 16271557
[TBL] [Abstract][Full Text] [Related]
15. The case for bladder botulinum toxin application.
Kim DK; Thomas CA; Smith C; Chancellor MB
Urol Clin North Am; 2006 Nov; 33(4):503-10, ix. PubMed ID: 17011386
[TBL] [Abstract][Full Text] [Related]
16. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
da Silva CM; Cruz F
Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.
Patki PS; Hamid R; Arumugam K; Shah PJ; Craggs M
BJU Int; 2006 Jul; 98(1):77-82. PubMed ID: 16831148
[TBL] [Abstract][Full Text] [Related]
18. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
[TBL] [Abstract][Full Text] [Related]
19. Refractory neurogenic detrusor overactivity.
Cruz F; Silva C
Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
